van Saene Hendrick K F, Petros Andy J, Ramsay Graham, Baxby Derrick
Department of Medical Microbiology, University of Liverpool, Duncan Building, Liverpool, UK.
Intensive Care Med. 2003 May;29(5):677-90. doi: 10.1007/s00134-003-1722-2. Epub 2003 Apr 10.
The objective was to compare evidence of the effectiveness, costs and safety of the traditional parenteral antibiotic-only approach against that gathered from 53 randomised trials involving more than 8,500 patients and six meta-analyses on selective decontamination of the digestive tract (SDD) to control infection on the intensive care unit (ICU). PHILOSOPHY: Traditionalists believe that all infections are due to breaches of hygiene except those established in the first 2 days, and that all micro-organisms can cause death. In contrast, newer insights show that transmission via the hands of carers are responsible only for infections occurring after one week, and that only a limited range of 15 potential pathogens contribute to mortality. INTERVENTIONS TO PREVENT ICU INFECTION: The traditional approach is based on hand disinfection aiming at the prevention of transmission of all micro-organisms, to control all infections that occur after 2 days on the ICU. The second feature is the restrictive use of systemic antibiotics, only in cases of microbiologically proven infection. In contrast, SDD aims to control the three types of infection: primary, secondary endogenous and exogenous due to 15 potential pathogens. The classical SDD tetralogy comprises four components: (i) a parenteral antibiotic, cefotaxime, administered for three days to prevent primary endogenous infections typically occurring "early"; (ii) the oropharyngeal and enteral antimicrobials, polymyxin E, tobramycin and amphotericin B administered in throat and gut throughout the treatment on the ICU to prevent secondary endogenous infections tending to develop "late"; (iii) a high standard of hygiene to control transmission of potential pathogens; and (iv) surveillance samples of throat and rectum to monitor the efficacy of the treatment.
(i) Infectious morbidity; (ii) mortality; (iii) antimicrobial resistance; and (iv) costs.
Properly designed trials on hand disinfection have never demonstrated a reduction in either pneumonia and septicaemia, or mortality. Two randomised trials using restrictive antibiotic policies failed to show a survival benefit at 28 days. In both trials the proportion of resistant isolates obtained from the lower ways was >60% despite significantly less use of antibiotics in the test group. A formal cost effectiveness analysis of the traditional antibiotic policies has not been performed. On the other hand, two meta-analyses have shown that SDD reduces the odds ratio for lower airway infections to 0.35 (0.29-0.41) and mortality to 0.80 (0.69-0.93), with a 6% overall mortality reduction from 30% to 24%. No increase in the rate of super infections due to resistant bacteria could be demonstrated over a period of 20 years of clinical research. Four randomised trials found the cost per survivor to be substantially lower in patients receiving SDD than for those traditionally managed.
The traditionalists still rely on level 5 evidence, i.e. expert opinion, with a grade E recommendation, whilst the proponents of SDD are able to cite level 1 evidence allowing a grade A recommendation in their attempts to control infection on the ICU. The main reason for SDD not being widely used is the primacy of opinion over evidence.
比较传统的仅使用肠外抗生素方法与从53项涉及8500多名患者的随机试验以及6项关于消化道选择性去污(SDD)以控制重症监护病房(ICU)感染的荟萃分析中收集的有效性、成本和安全性证据。理念:传统观念认为,除了最初两天内发生的感染外,所有感染都是由于卫生措施不到位所致,并且所有微生物都可能导致死亡。相比之下,新的见解表明,护理人员经手传播仅导致一周后发生的感染,并且只有15种潜在病原体中的有限种类会导致死亡。预防ICU感染的干预措施:传统方法基于手部消毒,旨在防止所有微生物的传播,以控制ICU中两天后发生的所有感染。第二个特点是全身性抗生素的限制性使用,仅在微生物学证实感染的情况下使用。相比之下,SDD旨在控制三种类型的感染:原发性、继发性内源性和外源性感染,这些感染由15种潜在病原体引起。经典的SDD四联疗法包括四个组成部分:(i)一种肠外抗生素头孢噻肟,给药三天以预防通常“早期”发生的原发性内源性感染;(ii)口咽和肠道抗菌药物多粘菌素E、妥布霉素和两性霉素B,在整个ICU治疗期间在咽喉和肠道给药,以预防倾向于“后期”发生的继发性内源性感染;(iii)高标准的卫生措施以控制潜在病原体的传播;以及(iv)咽喉和直肠的监测样本以监测治疗效果。
(i)感染发病率;(ii)死亡率;(iii)抗菌药物耐药性;以及(iv)成本。
设计合理的手部消毒试验从未证明能降低肺炎和败血症的发生率或死亡率。两项采用限制性抗生素政策的随机试验未能显示28天时的生存获益。在这两项试验中,尽管试验组使用的抗生素明显较少,但从下呼吸道分离出的耐药菌株比例均>60%。尚未对传统抗生素政策进行正式的成本效益分析。另一方面,两项荟萃分析表明,SDD将下呼吸道感染的优势比降至0.35(0.29 - 0.41),将死亡率降至0.80(0.69 - 0.93),总体死亡率从30%降至24%,降低了6%。在20年的临床研究期间,未发现耐药菌引起的二重感染率增加。四项随机试验发现,接受SDD治疗的患者每存活一名患者的成本显著低于传统管理的患者。
传统主义者仍然依赖5级证据,即专家意见,推荐等级为E,而SDD的支持者能够引用1级证据,在试图控制ICU感染时允许A等级推荐。SDD未被广泛使用的主要原因是观点优先于证据。